Company news: Pfizer, Sharecare

Share this article:
Pfizer, together with a number of health advocacy groups, is launching Get Old, a program aimed at fostering discussion of the aging process. It will be hosted on GetOld.com, “a new website that creates a unique online community where people can join discussions on the issues as well as read expert advice about them. Visitors can search for info on a host of topics including dealing with cancer and obesity, managing finances and plans for long-term care, as well as issues of concern to the “Sandwich Generation” of people caring for children and elderly relatives. Initial postings will be from health experts and employees at Pfizer and the other partners in the project, which include the Visiting Nurses Associations of America, the National Family Caregivers Association and Men's Health Network.

Sharecare acquired software developer PKC Corp., “a leading developer of healthcare decision support software that empowers patients and providers with individualized medical knowledge.” The Burlington, VT-based firm's system will be integrated into Sharecare's platform, “providing the healthcare providers socially-enabled on Sharecare with a powerful decision support technology that allows them to instantly develop a differential diagnosis or comprehensive management plan for any patient.” Consumers on the site will get access to a digital assessment tool through which they can easily forward results to physicians.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.